SPTX · Seaport Therapeutics, Inc. · Proposed Sales
$18.42
-0.53 (-2.80%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jun 8, 2026
The latest filing states the doubt was alleviated.
“the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company believes that its existing cash, cash equivalents and investments of $212.6 million as of March 31, 2026, together with the additional proceeds received from the IPO, will be sufficient to allow the Company to fund operations at least twelve months from the date that of these condensed consolidated financial statements are issued.”View the 10-Q filed Jun 8, 2026
Market Cap
$1.15B
Shares
53.53M
Volume · Oct 2
258.7K
Avg daily vol (3M)
179.97K
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
No Proposed Sales
No Form 144 proposed-sale notices are available for this stock yet.